| Exclusion Criteria: | 1) experiencing excessive allergic reaction;
2) receiving any medications which may interfere with Docetaxel (Taxotere®) treatment for subject's cancer;
3) experiencing any concomitant disease which might interfere with the diagnosis and treatment of epiphora
4) changed their hormone replacement or deprivation therapy (i.e., estrogen replacement or estrogen and androgen deprivation) program within three months of the baseline/screening visit or anticipate starting such a program during the course of the study;
5) anticipated contact lens wear during any portion of the study;
6) changed their treatment regimen of beta blocking agents, or cholinergic agonists within three months of the baseline/screening visit or anticipate changing, starting, or ending such a regimen during the course of the study;
7) use of ocular ointments (including over-the-counter ointments) within one week of the baseline/screening visit;
8) used topical (including ophthalmic) or systemic cyclosporine within 90 days of the baseline/screening visit;
9) diagnosed with acne rosacea and currently on any systemic tetracycline antibiotic or any other prescribed treatment such as metronidazole, or have used any prescribed treatment for acne rosacea in the past;
10) active ocular infection or inflammation in any eye;
11) active ocular allergy in any eye;
12) abnormal dilated fundus examination indicative of intraocular tumor presence;
13) corneal disorder or abnormality that affects cornea sensitivity or normal spreading of the tear film in any eye;
14) severe blepharitis or obvious inflammation of the lid margin in any eye which, in the judgment of the investigator, may interfere with the interpretation of the study results;
15) history of punctal occlusion, canalicular stenosis or nasolacrimal duct blockage.
16) unable to cannulate the puncta (grade 3 on the Canalicular Stenosis Scale);
17) unable to successfully irrigate the canaliculi;
18) Schirmer's Test – Standard Test (with anesthesia) result of </= 3 mm;
19) epiphora is due to reflex tearing resulting from dry eye syndrome;
20) history of anterior segment surgery or trauma in either eye which would affect corneal sensitivity (e.g., cataract surgery, LASIK, PRK or any surgery involving a limbal or corneal incision) within the last 12 months;
21) current use, use within 2 weeks prior to Day 0 (baseline) or likely to use during the study period of any topical ophthalmic medications (e.g., antibiotics, glaucoma medications) other than ophthalmic medications used in this study;
22) known allergy or hypersensitivity to Restasis® (cyclosporine A) and its excipients and/or FML Forte® (Fluorometholone 0.25%) and its excipients;
23) requirement for concomitant procedure(s)/therapy that would interfere with study objectives must cease use at least 4 weeks prior to enrollment and remain free from use of these procedures/therapies throughout duration of this study;
24) pregnant, nursing, or planning a pregnancy during the course of the study and females of childbearing potential, not using a reliable means of contraception;
25) clinically diagnosed by the investigator to have none to trace epiphora [grades 0 or 1on a five-point scale (0-4)] in either eye;
26) history of allergy or sensitivity to the other medications used in this study (Refresh Endura™) or their excipients;
27) history of herpetic eye disease;
28) any condition or situation which, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study. |